Dr. Lal PathLabs Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Dr. Lal PathLabs heeft een totaal eigen vermogen van ₹20.4B en een totale schuld van ₹417.0M, wat de schuld-eigenvermogensverhouding op 2% brengt. De totale activa en totale passiva bedragen respectievelijk ₹26.0B en ₹5.6B. De EBIT Dr. Lal PathLabs is ₹5.2B waardoor de rentedekking -17.3 is. Het heeft contanten en kortetermijnbeleggingen van ₹11.3B.
Belangrijke informatie
2.0%
Verhouding schuld/eigen vermogen
₹417.00m
Schuld
| Rente dekkingsratio | -17.3x |
| Contant | ₹11.27b |
| Aandelen | ₹20.35b |
| Totaal verplichtingen | ₹5.62b |
| Totaal activa | ₹25.98b |
Recente financiële gezondheidsupdates
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Recent updates
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results
Oct 26Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
Oct 24Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk
Oct 06These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
May 21What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital
Feb 13Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends
Sep 21These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00
Jul 31Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 23Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?
Jun 11Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹13.3B ) LALPATHLAB } overtreffen de korte termijn passiva ( ₹4.6B ).
Langlopende schulden: De kortetermijnactiva LALPATHLAB ( ₹13.3B ) overtreffen de langetermijnschulden ( ₹999.0M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: LALPATHLAB heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van LALPATHLAB is de afgelopen 5 jaar gestegen van 0% naar 2%.
Schuldendekking: De schuld van LALPATHLAB wordt goed gedekt door de operationele kasstroom ( 1286.7% ).
Rentedekking: LALPATHLAB verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.